Transgenic Nonhuman Animal (e.g., Mollusks, Etc.) Patents (Class 800/13)
  • Patent number: 10973844
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 13, 2021
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • Patent number: 10934555
    Abstract: A method of introducing naked dsRNA into a seed is provided. The method comprising contacting the seed with the naked dsRNA under conditions which allow penetration of the dsRNA into the seed, thereby introducing the dsRNA into the seed.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: March 2, 2021
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Amir Avniel, Efrat Lidor-Nili, Rudy Maor, Ofir Meir, Orly Noivirt-Brik, Osnat Yanai-Azulay
  • Patent number: 10925264
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) Lymphocyte Activation Gene 3 (LAG-3), and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 23, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd
    Inventors: Yuelei Shen, Yanan Guo, Chaoshe Guo, Yang Bai, Jiawei Yao, Lei Zhao, Rui Huang
  • Patent number: 10871487
    Abstract: Proteins (20) having glucose-binding sites (28) that bind to glucose (30) are described.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: December 22, 2020
    Assignee: GLUSENSE LTD.
    Inventors: Zohar Biron-Sorek, Uriel Barkai
  • Patent number: 10857196
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 8, 2020
    Assignee: BicycleTx Limited
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • Patent number: 10829833
    Abstract: The invention provides a process of isolating or enriching a heavy metal present in a liquid medium. The process comprising the following steps: (a) incubating a suspension containing (i) particulate scrap metal, household waste and/or industrial waste containing a heavy metal in elemental form and (ii) biomass comprising a bacterium, or a combination of two or more bacteria, capable of binding the heavy metal; (b) separating the biomass having bound heavy metal from the suspension of step (a); and (c) isolating the heavy metal from the biomass separated in step (b).
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: November 10, 2020
    Assignee: B.R.A.I.N. Biotechnology Research and Information Network AG
    Inventors: Stephen Gos, Andrea Christiansen, Xin Lu, Guido Meurer, Yvonne Tiffert, Esther Gabor, Benedikt Hoffmann, Martin Langer
  • Patent number: 10829772
    Abstract: The current invention provides a modular vector system that enables the insertion of gene expression cassettes in a recursive directional stacking fashion by rare restriction sites which requires only one type of vector. The invention also provides DNA molecules, compositions, and transgenic organisms, plants, plant tissues, plant seeds, and cells comprising recombined restriction sites for rare restriction enzymes.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: November 10, 2020
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Changlin Fu, Jinyuan Liu
  • Patent number: 10793616
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 6, 2020
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Tim Schnyder
  • Patent number: 10793843
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: October 6, 2020
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • Patent number: 10793921
    Abstract: The present invention is directed to a cellular biosensor system comprising (A) a repressor module comprising one or more genes, which in their cumulative gene action exert repressing and/or inhibitory effect(s) on (B), an output module comprising at least one gene comprising at least one output sequence generating one or more output signals (i) in the absence of repressing and/or inhibitory effect(s) of the repressor module (A) and (ii) in the presence of at least one recombinase expressed by (C), a recombinase module comprising at least one gene comprising at least one sequence encoding a site-specific recombinase that enables gene rearrangement in the output module resulting in one or more output signals in the absence of repressing and/or inhibitory effect(s) of the repressor module, wherein the repressing and/or inhibitory effects of the repressor module are controlled by one or more inputs that negatively affect the repressing and/or inhibitory effects of the repressor module (A).
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 6, 2020
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Nicolas Lapique
  • Patent number: 10744168
    Abstract: A GMP adapted to provide the PAL gene for the treatment of PKU when administered orally. The GMP of the present invention may include a probiotic, a PAL gene to be expressed using the probiotic, wherein the PAL gene is functionally attached to a promoter and a ribosome binding site, and may be codon-optimized for expression in a certain host organism. A method of treating the metabolic disease of PKU by oral administration and ingestion of a GMP is also provided.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: August 18, 2020
    Assignee: UNIVERSITY OF NORTH TEXAS
    Inventors: Katherine Durrer, Michael Allen, Ione Hunt von Herbing
  • Patent number: 10745680
    Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: August 18, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Zhiqian Liu, Arjan Van Der Flier, David R. Light, Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, John Kulman, Ayman Ismail
  • Patent number: 10689654
    Abstract: A bivalent siRNA chimera platform capable of efficiently delivering and silencing two or more genes in vivo or in vitro is provided. Methods of using the bivalent siRNA chimeras for selectively targeting cells to down-regulate the expression of multiple genes are also provided.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Hong Yan Liu
  • Patent number: 10676750
    Abstract: In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and DNA constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from Pichia pastoris wherein the nucleic acids have promoter activity are described. The invention also relates to expression methods, host cells, expression vectors, and DNA constructs, for using the Pichia pastoris promoters to produce proteins and polypeptides, and to the proteins and polypeptides produced using the expression methods.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 9, 2020
    Assignee: Biogrammatics, Inc.
    Inventors: Ilya I. Tolstorukov, James M. Cregg, Thomas G. Chappell, Knut R. Madden
  • Patent number: 10660318
    Abstract: Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: May 26, 2020
    Assignee: Tosk, Inc.
    Inventors: Travis Karg, William A. Garland, Steve Yanofsky
  • Patent number: 10590440
    Abstract: The present invention relates to the production of hydrolyzates from a lignocellulose-containing material, and to fermentation of the hydrolyzates. More specifically, the present invention relates to the detoxification of phenolic inhibitors and toxins formed during the processing of lignocellulose-containing material by enzymatically sulfating the phenolic inhibitors and toxins using aryl sulfotranseferases.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 17, 2020
    Assignee: CysBio ApS
    Inventors: Christian Bille Jendresen, Alex Toftgaard Nielsen
  • Patent number: 10570200
    Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: February 25, 2020
    Assignee: California Institute of Technology
    Inventors: Bruce A. Hay, Juan Li
  • Patent number: 10550400
    Abstract: The invention relates to transgenic plants comprising an inverted-repeat construct which triggers post-transcriptional gene silencing of an endogenous visual reporter gene driven by a tissue-specific promoter wherein said tissue is relevant for pathogen entry, propagation or replication and their uses for screening natural or synthetic molecules, microorganisms or extracts from micro- or macro-organisms for their potential ability to inhibit pathogen entry, propagation or replication in plants by enhancing PTGS or for characterizing the mode of action of natural or synthetic molecules that are known to enhance plant disease resistance through an ill-defined mode of action.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: February 4, 2020
    Assignees: Paris Sciences et Lettres—Quartier Latin, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Lionel Navarro, Odon Thiebeauld
  • Patent number: 10448622
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignees: E. R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co., Ltd
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 10383948
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 20, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Mark Anderson, Louie Naumovski, Edward B. Reilly, Jieyi Wang
  • Patent number: 10378007
    Abstract: Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: August 13, 2019
    Assignee: CELLECTIS
    Inventors: Alexandre Juillerat, Philippe Duchateau
  • Patent number: 10370420
    Abstract: Genetically encoded, photocleavable proteins are derived from a fluorescent protein. Upon illumination, the proteins photocleave and spontaneously dissociate into two or more fragments or release one end of an internal loop.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: August 6, 2019
    Inventors: Robert Campbell, Wei Zhang, Hiofan Hoi
  • Patent number: 10342221
    Abstract: Pericytes are mural cells of brain capillaries that degenerate in multiple neurological disorders. Pericytes regulate neurovascular functions, but their role in the adult brain and disease is still poorly understood because of the lack of adequate pericyte-specific experimental models. All current pericyte-deficient models are not pericyte specific, and carry an inherited embryonic trait. Here, the Inventors generated an inducible pericyte-specific Cre line using a double-promoter strategy. The Inventors ablated adult mouse pericytes expressing Cre-dependent diphtheria toxin receptor after toxin administration. Pericyte ablation led to a rapid dysregulation of cerebral blood flow and blood-brain barrier breakdown. This was followed by behavioral deficits and neurodegenerative changes. These findings show that circulatory deficits leading to secondary neurodegeneration develop immediately after pericyte loss.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 9, 2019
    Assignee: University of Southern California
    Inventors: Berislav Zlokovic, Zhen Zhao
  • Patent number: 10338082
    Abstract: The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: July 2, 2019
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti, Alain Sarasin, Denis Biard
  • Patent number: 10300147
    Abstract: The present disclosure describes the role for miR-322(424)/503 in the differentiation of cardiac precursor cells. Thus, the use of these molecules in the programming of resident stem/progenitor cells into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: May 28, 2019
    Assignee: University of Houston System
    Inventors: Yu Liu, Robert Schwartz, Xiaopeng Shen
  • Patent number: 10301614
    Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 28, 2019
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton
  • Patent number: 10240161
    Abstract: A method of introducing naked dsRNA into a seed is provided. The method comprising contacting the seed with the naked dsRNA under conditions which allow penetration of the dsRNA into the seed, thereby introducing the dsRNA into the seed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: March 26, 2019
    Assignee: A.B. Seeds Ltd.
    Inventors: Amir Avniel, Efrat Lidor-Nili, Rudy Maor, Ofir Meir, Orly Noivirt-Brik, Osnat Yanai-Azulay
  • Patent number: 10172880
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 8, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • Patent number: 10030235
    Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 24, 2018
    Assignee: Hiroshima University
    Inventors: Takashi Yamamoto, Tetsushi Sakuma, Hiroshi Ochiai, Shinya Matsuura, Tatsuo Miyamoto
  • Patent number: 10007766
    Abstract: A method is disclosed of predicting cancer patient response to immune checkpoint inhibitors, e.g., an antibody drug blocking ligand activation of programmed cell death 1 (PD-1) or CTLA4. The method includes obtaining mass spectrometry data from a blood-based sample of the patient, obtaining integrated intensity values in the mass spectrometry data of a multitude of pre-determined mass-spectral features; and operating on the mass spectral data with a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of melanoma patients with a classification algorithm and generates a class label for the sample. A class label “early” or the equivalent predicts the patient is likely to obtain relatively less benefit from the antibody drug and the class label “late” or the equivalent indicates the patient is likely to obtain relatively greater benefit from the antibody drug.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: June 26, 2018
    Assignee: Biodesix, Inc.
    Inventors: Joanna Röder, Krista Meyer, Julia Grigorieva, Maxim Tsypin, Carlos Oliveira, Arni Steingrimsson, Heinrich Röder, Senait Asmellash, Kevin Sayers, Caroline Maher, Jeffrey Weber
  • Patent number: 9974290
    Abstract: The invention concerns a non-human animal model useful for sensitively studying gene-gene interactions over a wide genetic background; methods for producing the animal model; and methods for studying gene-gene interactions using an animal model of the invention.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 22, 2018
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jia-Wang Wang, Richard F. Lockey
  • Patent number: 9957487
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 1, 2018
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Patent number: 9902970
    Abstract: The invention relates to large-scale production of human antibodies by transgenic animals with high production of fully human IgG up to >10 g/L in sera with human IgG1 subclass dominancy. This invention also supports a feasibility of complex chromosome engineering for complicated genetic studies in non-murine mammalian species.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: February 27, 2018
    Assignee: SAB, LLC
    Inventors: Yoshimi Kuroiwa, Hiroaki Matsushita, Akiko Sano
  • Patent number: 9902979
    Abstract: Provided is a method for producing ambrein, comprising reacting tetraprenyl-?-curcumene cyclase with 3-deoxyachilleol A to obtain ambrein.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: February 27, 2018
    Assignee: Niigata University
    Inventors: Tsutomu Sato, Daijiro Ueda, Tsutomu Hoshino
  • Patent number: 9844605
    Abstract: The present invention relates to methods and compositions for high content drug screening in Caenorhabditis elegans which may be used to identify compounds that treat disorders associated with protein aggregation. It is based, at least in part, on the discovery that Caenorhabditis elegans, genetically modified to create a model system for disorders of protein aggregation, could be used, in a high throughput screening system, to identify agents that reduce the amount of aggregated protein.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 19, 2017
    Assignee: THE UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • Patent number: 9763897
    Abstract: A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wherein the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. The composition includes 0.5 to 12 mg of astaxanthin and may be used to treat low density lipoprotein (LDL) oxidation in humans and other diseases, disorders and impairments.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: September 19, 2017
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 9758775
    Abstract: Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: September 12, 2017
    Assignees: Regents of the University of Minnesota, Iowa State University Research Foundation, Inc.
    Inventors: Daniel F. Voytas, Adam J. Bogdanove, Feng Zhang
  • Patent number: 9695245
    Abstract: The present invention relates to the preparation of substantially purified anti-EDA1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of EDA1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles. The anti-EDA1 antibodies are also useful in immunoassays such as sandwich ELISA.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 4, 2017
    Assignee: EDIMER PHARMACEUTICALS, INC
    Inventors: Pascal Schneider, Neil Kirby, Christine Kowalczyk-Quintas, Anh Thu Dang
  • Patent number: 9562239
    Abstract: The invention relates to a process of process of producing a fermentation product, comprising: liquefying a starch-containing material to dextrins with an alpha-amylase in the presence of an asparaginase and/or an amino acid oxidase; saccharifying the dextrins to a sugar with a glucoamylase; and fermenting the sugar using a fermenting organism.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 7, 2017
    Assignee: NOVOZYMES NORTH AMERICA, INC.
    Inventors: Rogerio Prata, Alison Robey, Todd Forman, Suzanne Clark, Eder Manzini Bordin
  • Patent number: 9499838
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: November 22, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD., E. R. SQUIBB & SONS, L.L.C.
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 9476027
    Abstract: The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Ig? and/or Ig? sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Ig? and/or Ig? sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Ig? and/or Ig? results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 25, 2016
    Assignee: Roche Diagnostics GMBH
    Inventor: Roland Buelow
  • Patent number: 9404125
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 2, 2016
    Assignee: CRYSTAL BIOSCIENCE, INC.
    Inventors: William Don Harriman, Robert Etches, Phil Leighton
  • Patent number: 9393257
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: July 19, 2016
    Assignee: Regents of the University of Minnesota
    Inventors: Mark J. Osborn, Jakub Tolar, Bruce Blazar, Daniel F. Voytas
  • Patent number: 9394372
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: July 19, 2016
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 9382520
    Abstract: Secreted luciferases which are different from those known heretofore have been desired. The present invention provides a luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 5, 2016
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Patent number: 9359599
    Abstract: Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with improved specificity and methods for generating and using such TALEs.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: June 7, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, John Paul Guilinger, Vikram Pattanayak
  • Patent number: 9260726
    Abstract: Disclosed herein are methods and compositions for targeted integration of a exogenous sequence into a predetermined target site in a genome for use, for example, in protein expression and gene inactivation.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 16, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Edward J. Rebar, Fyodor Urnov
  • Patent number: 9232776
    Abstract: Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: January 12, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Andrew J. Murphy
  • Patent number: 9204624
    Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: December 8, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 9156911
    Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: October 13, 2015
    Assignee: AMGEN INC.
    Inventors: Shu-Chen Lu, Minghan Wang